Due to the fact that mRNA technology allows the production of diverse vaccines and
treatments in a shorter time frame and with reduced expense compared to conventional …

The therapeutic use of messenger RNA (mRNA) has fueled great hope to combat a wide
range of incurable diseases. Recent rapid advances in biotechnology and molecular …

To date, the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) has determined 399,600,607 cases and 5,757,562 …

Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

A drawback of the current mRNA-lipid nanoparticle (LNP) COVID-19 vaccines is that they
have to be stored at (ultra) low temperatures. Understanding the root cause of the instability …

Recent advances in the generation, purification and cellular delivery of RNA have enabled
development of RNA-based therapeutics for a broad array of applications. RNA therapeutics …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late
2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) …

The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the
development of lipid nanoparticle delivery systems that not only efficiently express the …

Vaccines are one of the most important tools in public health and play an important role in
infectious diseases control. Owing to its precision, safe profile and flexible manufacturing …

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine
agent in a preclinical study nearly 30 years ago, numerous advances have been made in …